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Background: Avascular osteonecrosis (AVN) is a serious 
osseous complication after renal transplantation (RT). Its 
prevalence clearly decreased from 20% to 4 % possibly 
due to the use of calcinurin inhibitors (CNI), reduction of 
steroid doses and use of steroid free regimens. The aim 
of our study was to evaluate the frequency of AVN 
among our kidney transplant recipients and to determine 
the risk factors for its occurrence. 
Patients and methods: Among 1785 kidney transplant 
recipients who received renal allografts between March 
1976 and December 2005, 40 patients (2.24%) developed 
AVN with a mean age of 31.3 ± 10.2 years. Eighty 
kidney transplant recipients without AVN were selected 
to be a matched control group. The localization of AVN 
was the femoral head in all cases. 
Results: AVN was diagnosed at a mean of 20.4 months 
after transplantation. The following risk factors were 
statistically significant; sirolimus-based regimen, 
hypercholesterolemia, overweight with body mass index 
(BMI)>26 and those with HLA A9, HLA B35 and DR 
B15.  
Conclusions: We concluded that the proper management 
of hypercholesterolemia, maintenance of ideal body 
weight as well as avoidance of sirolimus-based 
immunosuppressive regimen in genetically predisposed 
patients may be an effective preventive strategy to avoid 
AVN. 
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Renal transplantation (RT) is the treatment of choice for 
most patients with end stage renal disease (ESRD). 
However, it is attended by complications which are many 
and varied osseous complications after RT include 
osteoporotic fractures and osteonecrosis. It has been 
estimated that osteonecrosis of the femoral head affect up 
to 20% of recipients. Symptomatic cases of avascular 
necrosis (AVN) of femoral head are almost always 
serious complications, accounting for considerable 
functional restriction and eventual disability, ultimately 
leading to femoral collapse and total hip arthroplasty in 
over 80% of cases [1]. X-rays are usually normal at the 
early stage of bone disease, whereas magnetic resonance 
imaging (MRI) is more sensitive and specific for the 
diagnosis of AVN [2]. 
The known risk factors for AVN include high cumulative 
steroid dose, blood urea nitrogen level, hypofibrinolysis 
caused by variant plasminogen activator inhibitor-1 
genotype and allograft rejection. In children, the risk 
factors for osteonecrosis are poorly known, although age 
under 10 years seems to decrease the risk and higher 
cumulative steroid doses to increase the risk of AVN [3]. 
If the diagnosis is made in early phase, treatment by 
bisphosphonate infusion and vascular bone grafting may 
be beneficial. Secondary deformities and osteoarthritis 
are treated with corrective osteomies and total joint 
replacement [4]. 
We retrospectively reviewed our renal transplant 
recipients followed between March 1976 and December 
2005 to identify the frequency and the risk factors for the 






Material and methods 
 
Between March 1976 and December 2005, 1785 kidney 
transplantations were performed. Forty cases of 
symptomatic AVN were diagnosed by X-ray exams, or 
MRI. The demographic characteristics, clinical features, 
immunosuppressive protocol, rejection history, 
cumulative dose of corticosteroids, posttransplantation 
weight gain, duration on dialysis before RT, original 
kidney disease, HLA and DR loci and serum creatinine 
of these patients were compared  with 80 matched renal 
transplant recipients without AVN. 
Different strategies for management of AVN either core 
decompression or hip replacements were also studied. 
Statistical analysis: Qualitative data were displayed in 
cross tabulation and quantitative data were described of 
arithmetic mean ± SD. Vicariate techniques were used 
for initial evaluation of contrast. Thus, the chi-square and 
fisher exact test were used for comparison of frequencies 
of qualitative variables and unpaired t test was used for 
comparison of means of two quantitative variables. P 
value <0.05 was considered significant. All analyses 
were carried out using the computer package SPSS for 




The 40 patients with AVN of the femoral head included 
32 men and 8 women. The mean age was 31.3 ± 10.2 
years. The demographic characteristics, clinical 
information and biochemical data of the 40 patients with 
AVN and the 80 control patients are summarized in 
table(1). The original kidney disease, duration of 
dialysis, pretransplant corticosteroid use as well as the 
body mass index were compared with control group. 
Table (2) shows that HLA-A9, B35 and DR-B15 were 
significantly higher among AVN group compared to that 
of control. Serum cholesterol was significantly higher in 
the AVN group at initial evaluation and continued to be 
higher at time of diagnosis of AVN (table 1, 2). ON the 
other hand, the cumulative dose of steroid and the 
incidence of acute rejection episode were closely similar 
in both groups. Body mass index was found to be 
significantly higher among recipients of AVN (p=0.05). 
It is noteworthy that, the incidence of AVN was 
significantly higher among patients with sirolimus-based 
immunosuppressive regimen being 6.5% compared to 
those maintained on other regimens (1.8%), p=0.0001 
(table 3). 
 





(n = 40) 
 
Control group 
(n = 80) 
P -value 
 
Mean age (years ) 
 
31.3 ± 10.2 
 
30.3 ± 9.4 
 
0.8 
Gender (male / female) 32/8 64/16 0.7 
Original kidney disease  







     - Non glomerular 9 (22.5%) 23 (28.9%) 0.8 
     - Not identified 23 (57.5%) 45 (56.1%) 0.8 
Prior hemodialysis 34 (84.6%) 71 (90.6%) 0.7 
Prior peritoneal dialysis  1 (2.9%) 1 (1.4%) 0.6 
Pre- emptive transplantation 5 (12.5%) 8 (10%) 0.7 
Duration of dialysis (months) 27.8 ± 12.8 27.9 ± 12.5 0.7 
Prior corticosteroid therapy 8(20%) 6 (7.5%) 0.8 
Duration of transplantation (months) 21.4 ± 2.7 21.3 ± 2.7 0.9 
Body mass index 22.9 ± 4.9 22.8 ± 4.3 0.7 
Serum cholesterol (mg/ dl) 
 
111.5 ± 54.7 
 










(n = 40) 
 
Control Group 
(n = 80) 
P-value 
 
Acute rejection episode 
 
0.33 ± 0.64 
 
0.31 ± 0.61 
 
0.7 
Cumulative mean dose of steroid (gm) 12.3 ± 15.3 11.5 ± 13.7 0.98 
DEXA Scan (T score) -1.39 ± 0.6 -1.6 ± 0.8 0.8 
BMI 26.4 ± 4.6 24.7 ± 4.2 0.05 
HLA – A 9 8 (20%) 4 (5%) 0.009 
HLA – B 35 5 (12.5%) 2 (2.5%) 0.02 
HLA – DR – B 15 7 (17.5%) 5 (6.3%) 0.04 
Serum creatinine (mg/dl) 1.59 ± 0.7 1.45 ± 0.5 0.3 
Serum cholesterol (mg/dl) 
 
206 ± 58.9 
 







































Figure 1 shows, T1-waighted coronal magnetic 
resonance (MR) images of a 37-year old male. He 
reported hip and groin pain on the left side. The MR 
images show ostenonecrosis of the femoral head with 
bone edema on the left side. Another 30-year old male 
patient experienced bilateral AVN of the femoral heads. 
Figure 2 show the same above mentioned changes but 
more on the right side. 
 
   
Fig. 1 a Fig. 1 b Fig. 1 c 
 
Fig. 1. Unilateral avascular necrosis: The left femoral head showing abnormal subchondrial area of low SI at T1WI (a), high SI at T2WI (b) surrounded by 
adjacent marrow oedema of high SI at STIR (c). 
 
  
Fig. 2 a Fig. 2 a 
 
Fig. 2. Bilateral avascular necrosis (AVN) of both femoral heads with mild joint effusion: Both femoral heads are seats of irregular line of granulation 




Osteoarticular diseases are common in solid organ 
transplant recipients. The underlying pathophysiology is 
a complex one. Patients with renal failure have 
multifactorial bone disease already prior to 
transplantation. After transplantation, several factors 
contribute to osteoarticular disease [5]. In the current 
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retrospective study, we observed symptomatic AVN in 
2.24%. This frequency is probably an underestimate 
since the screening of AVN was not systematic and 
imaging exams were performed when patients 
complained of articular pain evoking AVN. The use of 
steroid-sparing regimens has dramatically reduced the 
incidence of AVN from 20% to no more than 5 % [6].
 
 A 
review of literatures revealed that the time interval 
between transplantation and the development of AVN 
ranges between five and 126 months [7] and it was 20.4 
months in our study. 
Glucocorticoids are a risk factor for AVN. In 90% of 
cases the femoral head is affected. Implantation of a total 
hip replacement during the further course is often 
unavoidable in such cases [18]. We found that steroid-
free regimen as a primary immunosuppression was not 
associated with a lower incidence of hip AVN compared 
with other immunosuppressive protocols and this differs 
with other reports [8,9] that attributed this to possible 
alteration in circulating lipids with resultant microemboli 
in the arteries supplying bone. Another theory proposing 
that steroids induce changes in venous endothelial cells 
leading to stasis, increased intraosseous pressure and 
eventual necrosis [10]. We could attribute our opposing 
results to the relatively small number of patients on 
steroid-free regimen.  On the other hand, we found no 
correlation between post transplant AVN and total dose 
of steroids till diagnosis of AVN or the number of steroid 
pulses used for acute rejection episodes. Chen and 
associates [11] reported the same findings and explained 
these results by the possible genetic predisposition and 
idiosyncratic response to corticosteroids determined by 
undefined physiological factors. Moreover, Koo and 
colleagues [12] found that the total dose of steroid used 
until AVN was diagnosed by MRI ranged from 1.8 to 
15.5 gm of prednisolone or its equivalent. In our results, 
the cumulative dose of steroids was higher in AVN 
group (12.7 gm) compared with 11.4 gm in the control 
group but this did not attain statistical significance. 
On focusing on different immunosuppressive regimens, 
we found a highly significant correlation between post 
transplant AVN and the use of sirolimus-based regimen 
(6.5% versus 1.8% in non sirolimus-based regimen, 
p<0.0001). Bhandari and Eris [12] reported the same 
findings and explained this by the adverse lipid profile 
induced by sirolimus, its potent bone marrow suppressive 
effect or perhaps an idiosyncratic effect. 
Also, our results showed significant correlation between 
post transplant AVN and hypercholesterolemia either 
before or after transplantation. These results agree with 
that reported by Moscal et al. [13]. This could be 
explained by the fact that hypercholesterolemia could 
lead to subchondral fat emboli and endothelial damage. 
Therefore, monitoring and treatment of hyper-
cholesterolemia should be an essential target after 
transplantation. 
Tsakiris et al. [14] found that excessive weight gain 
(>10kg) in the first 6 months after RT has been 
demonstrated to be an additional risk factor for the 
development of AVN. This coincides with our results 
which showed that the body mass index (BMI) at time of 
diagnosis of AVN was significantly higher than that of 
control group (P=0.05). Inoue and Ono [15] attributed 
this to the mechanical overload exerted on the weak 
weight bearing hip joint or microfractures that can induce 
changes in the blood supply leading to AVN.       
Interestingly, we found predominant loci in the AVN 
group which are: HLA A9 (P=0.009), HLA B35 
(P=0.02) and HLA DR B15 (P=0.04), denoting that 
patients with these loci could be genetically predisposed 
to osteonecrosis. The genetic basis for hip AVN was 
studied by Chen et al. [11] and their results indicated that 
a 15-cM region between D12S1663 and D12S1632 in 
chromosome 12 q13 might harbor a gene for AVN of the 
femoral head. 
About 55% of our patients were managed by core 
decompression only, 20% by hip replacement, and 12.5% 
by core decompression followed by hip replacement 
while the remaining were managed conservatively. Core 
decompression is effective only in early stages. So, the 
use of MRI in suspected and high risk patients should be 
adopted after transplantation [5,7]. 
Conclusion: The incidence of posttransplant AVN of the 
femoral head was 2.24% among our cases. The most 
important risk factors for the development of AVN 
include; recipients with HLA A9, HLA B35 & DR B15, 
BMI > 26: Hypercholesterolemia and sirolimus-based 
immunosuppressive regimen. Steroid-free regimen 
deserves further evaluation as it seems a logic tool to 
lower the incidence of AVN. Finally, kidney transplant 
recipients should be advised to maintain ideal body 
weight and it is crucial to monitor and treat 
hypercholesterolemia. Moreover, it seems wise to adopt 
steroid and sirolimus-free immunosuppressive regimen 
for kidney transplant candidates having the above 
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